Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic therapy as palliative treatment for recurrent squamous cell carcinoma of the head and neck region
2004-004452-39Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2004
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temoporfin in head and neck squamous cell carcinoma (HNSCC), sponsored by Rigshospitalet. Primary endpoint: Tumour response according to WHO criteria. Started Dec 2004; status: completed.
02
Drugs
temoporfin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2004-004452-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004452-39.